GlassScriptPhysician profile
Mitchell A Willoughby
NPI 1134247570
$606.27
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $71.54 · 2023: $141 · 2024: $98.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.72 | 2019-2023 | Saxenda, Wegovy |
| Hologic Sales and Service, LLC | $44.04 | 2023 | Aptima |
| Amgen INC. | $43.25 | 2023-2024 | Repatha, Otezla |
| Lilly USA, LLC | $42.55 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $41.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.85 | 2019 | |
| Xeris Pharmaceuticals, INC. | $37.42 | 2023-2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $24.82 | 2019 | |
| Phadia US INC. | $24.59 | 2019 | |
| Astellas Pharma US INC | $23.89 | 2019 | |
| Pfizer INC. | $22.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.27 | 2020 | |
| Cequr Corporation | $16.52 | 2024 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $16.42 | 2020 | |
| Merck Sharp & Dohme LLC | $16.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qiagen, LLC | $15.46 | 2024 | |
| Glaxosmithkline, LLC. | $15.32 | 2024 | Arexvy, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $13.77 | 2019 | |
| Abbvie INC. | $13.18 | 2023 | Vraylar |
| Allergan, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Willoughby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.